JTTT

10.3000.00%
AG

Arjun Goyal

Independent Director

Dr. Arjun Goyal, M.D., M.Phil, M.B.A., is a life sciences investor and entrepreneur and the Founder and Managing Partner of Vianti Capital, a therapeutics-focused investment firm. He is Independent Director of JATT II Acquisition Corp. from April 16, 2026. He is an Independent Director of JATT III Acquisition Corp. since August 25, 2026. Dr. Goyal is a Co-Founder & Director at Affini-T Therapeutics, Inc. Dr. Goyal is Director of Halda Therapeutics, LLC since August 2024. Dr. Goyal served as a Director at Quanta Therapeutics, Inc. until 2025. Dr. Goyal was a Director of Scorpion Therapeutics, Inc. He was Independent Non-Executive Director at Centessa Pharmaceuticals plc (formerly Centessa Pharmaceuticals Limited) since January 29, 2021 until June 24, 2026. He serves as a Director of Alterome Therapeutics Inc. Dr. Goyal is a Co-Founder and Managing Director of Vida Ventures, a life sciences investment firm that he co-founded in 2017. Dr. Goyal served as a Director on the boards of Quanta Therapeutics, Affini-T and has played key roles in Vida Venture’s investments in Homology Medicines (NASDAQ:FIXX). Pionyr Immunotherapeutics (acquired), Peloton Therapeutics (acquired) and Asklepios BioPharmaceutical (acquired). He served as Director of Corporate Development and Board Observer at Pear Therapeutics Inc. He served as an Associate at 5AM Venture Management LLC. Prior to joining 5AM Ventures in 2014, Dr. Goyal was co-Founder of Foresight Pharmaceuticals. In his career, he served as an Analyst in global health policy at the Australian Mission to the United Nations. has served as our independent director since April 2026. Dr. Goyal is a life sciences investor and entrepreneur and the Founder and Managing Partner of Vianti Capital, a therapeutics-focused investment firm. Prior to founding Vianti, Dr. Goyal was a Co-Founder and Managing Director of Vida Ventures, a U.S.-based life sciences venture capital firm with over 1.7 billion in assets under management. He co-founded Vida in 2017 and departed the firm in December 2024 following multiple realized exits and the scaling of the platform. During his tenure, he served as the originating and lead partner on multiple investments, including Pionyr Immunotherapeutics (acquired by Gilead), Peloton Therapeutics (acquired by Merck), Asklepios BioPharmaceutical (acquired by Bayer), Scorpion Therapeutics (acquired by Eli Lilly), Halda Therapeutics (acquired by Johnson & Johnson), Homology Medicines (NASDAQ: FIXX), Kinnate Therapeutics (NASDAQ: KNTE), Alterome Therapeutics, Quanta Therapeutics and Third Arc Bio, with active governance involvement across multiple companies. Earlier in his career, from 2014 to 2017, Dr. Goyal was an investment professional at 5AM Ventures, a life sciences-focused venture firm. There, he co-led investments in companies including Aprea AB (NASDAQ: APRE), Spyryx, Pear Therapeutics, Portal Instruments, Entrada Therapeutics (NASDAQ: TRDA) and Homology Medicines (NASDAQ: FIXX) and served as a Board Observer across multiple portfolio companies. Dr. Goyal has also been serving as a director of Centessa Pharmaceuticals Plc since January 2021. Dr. Goyal trained as a physician and brings a combined clinical, scientific and business background to his investment work. He earned his M.D. from the University of Melbourne, completed medical research training at the University of Oxford, received an M.Phil. in Bioscience Enterprise from the University of Cambridge as a Commonwealth Scholar and Gates Cambridge Scholar and holds an MBA from Harvard Business School. He completed postgraduate medical training in Internal Medicine at the University of Sydney. He has received several professional recognitions, including the Advance Award for Technology & Entrepreneurship for Global Australians (2021) and selection as one of Australia’s 25 Most Influential Global Game-Changers in Business (2026). He serves on the Board of Advisors for the MS/MBA Life Sciences Program at Harvard Business School, the American Australian Association Education Fellowship Committee and the Investment Committee of the University of Melbourne Technology Endowment Fund.

Positions